Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data Clearmind Medicine Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2023
FY2023
FY2024
FY2025
Research and development
0.47
3.08
1.54
1.38
2.06
Selling, general and administrative
2.22
3.17
4.76
4.36
Pre-tax income
-2.73
-6.87
-8.6
-4.88
-3.79
Income tax
0.03
0.02
0.38
0.07
Net income
-2.73
-6.89
-8.62
-5.25
-3.86
EPS, basic
-3,526.00
-6,364.00
-1,703.00
-67.80
-30.35
EPS, diluted
-3,526.00
-6,364.00
-1,703.00
-67.80
-30.35
Balance sheet
FY2021
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
3.37
0.13
5.43
6.57
3.92
Short-term investments
0.09
0.29
1.66
Total current assets
0.43
5.79
7.09
5.95
Property, plant and equipment
0.01
0
Lease right-of-use assets
0.04
0.05
0.02
Intangible assets
0.13
0.12
0.11
0.1
Total assets
0.83
5.95
7.26
6.08
Accounts payable
0.62
0.53
Total current liabilities
4.97
4.13
4.89
Lease liabilities
0.02
Total liabilities
1.93
4.97
4.15
4.89
Paid-in capital
6.71
17.1
24.2
26.4
Retained earnings
-10.1
-18.8
-24
-27.9
Total equity
3.52
-1.11
0.98
3.11
1.19
Total liabilities and equity
0.83
5.95
7.26
6.08
Cash flow statement
FY2021
FY2023
FY2023
FY2024
FY2025
Net income
-2.73
-6.89
-8.62
-5.25
-3.86
Cash from operations
-2.08
-3.72
-6.3
-4.86
-4.73
Capital expenditures
-0.02
-0.01
Cash from investing
-0.18
-0.01
-0.03
-0.24
-0.54
Stock issued
0.08
Cash from financing
5.39
0.51
11.7
6.25
2.62
Exchange rate effect
-0.02
-0.04
-0.01
0
Net change in cash
3.13
-3.24
5.3
1.15
-2.65
Free cash flow
-2.09
-3.73
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $0.80 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-57.8%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
-16.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
94.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.22x
Current assets / current liabilities.
Quick ratio
1.14x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.14x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
80.4%
Total liabilities / total assets.
Working capital
$1.1M
Current assets - current liabilities.
Goodwill and intangibles / assets
1.6%
(Goodwill + intangible assets) / total assets.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$30.35
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$30.35
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$818.3K
Share price x shares outstanding.
Enterprise value
-$4.8M
Market cap + total debt - cash - short-term investments.
Earnings yield
-471.4%
Net income / market cap (the inverse of P/E).
Was Clearmind Medicine Inc. profitable in fiscal 2025?
No. It reported a net loss of $3.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.